Strongbridge Biopharma plc (NASDAQ:SBBP) – Cantor Fitzgerald issued their FY2017 EPS estimates for shares of Strongbridge Biopharma in a research note issued to investors on Wednesday. Cantor Fitzgerald analyst E. Piros expects that the biotechnology company will post earnings per share of ($2.84) for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. Cantor Fitzgerald also issued estimates for Strongbridge Biopharma’s FY2018 earnings at ($1.23) EPS.

A number of other research firms have also issued reports on SBBP. Zacks Investment Research lowered Strongbridge Biopharma from a “hold” rating to a “sell” rating in a research report on Wednesday, October 4th. ValuEngine lowered Strongbridge Biopharma from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price target on shares of Strongbridge Biopharma in a research report on Wednesday, November 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $12.25.

Shares of Strongbridge Biopharma (SBBP) opened at $6.40 on Monday. The company has a quick ratio of 4.61, a current ratio of 4.70 and a debt-to-equity ratio of -1.89. Strongbridge Biopharma has a 12-month low of $2.00 and a 12-month high of $8.85.

Hedge funds and other institutional investors have recently modified their holdings of the company. State of Wisconsin Investment Board acquired a new stake in shares of Strongbridge Biopharma during the 2nd quarter worth about $114,000. Rhumbline Advisers acquired a new position in Strongbridge Biopharma during the second quarter worth approximately $154,000. California State Teachers Retirement System acquired a new position in Strongbridge Biopharma during the second quarter worth approximately $277,000. Teachers Advisors LLC acquired a new position in Strongbridge Biopharma during the second quarter worth approximately $297,000. Finally, Bank of New York Mellon Corp acquired a new position in Strongbridge Biopharma during the second quarter worth approximately $331,000. 57.53% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Strongbridge Biopharma plc (SBBP) to Post FY2017 Earnings of ($2.84) Per Share, Cantor Fitzgerald Forecasts” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2017/12/11/strongbridge-biopharma-plc-sbbp-to-post-fy2017-earnings-of-2-84-per-share-cantor-fitzgerald-forecasts.html.

About Strongbridge Biopharma

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.

Receive News & Ratings for Strongbridge Biopharma plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma plc and related companies with MarketBeat.com's FREE daily email newsletter.